利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.059 秒)

    Benzoxazepine Compound
    4.
    发明申请
    Benzoxazepine Compound 审中-公开
    苯并西泮化合物

    公开(公告)号：US20080227770A1

    公开(公告)日：2008-09-18

    申请号：US10566883

    申请日：2004-07-30

    申请人： Shogo Marui ,  Takashi Miki ,  Shoutarou Miura ,  Tomoyuki Nishimoto ,  Yoshihisa Nakada

    发明人： Shogo Marui ,  Takashi Miki ,  Shoutarou Miura ,  Tomoyuki Nishimoto ,  Yoshihisa Nakada

    IPC分类号： A61K31/553 ,  C07D267/02 ,  A61P3/00

    CPC分类号： C07D413/06 ,  C07D267/14 ,  C07D417/06

    摘要： A compound represented by the formula [1]: wherein ring A and ring B each represent an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl group optionally substituted with an optionally substituted hydroxyl group; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; x2 represents a bond, —O— or —S—; X3 represents a bond or an optionally substituted divalent hydrocarbon group; Y represents an optionally esterified or amidated carboxyl group, or a salt thereof. The compound of the formula [I] is safer and has more potent lipid lowering activity such as squalene synthase inhibitory activity (cholesterol lowering activity) and triglyceride lowering activity, and thus it is a compound useful as an agent for preventing or treating hyperlipemia.

    摘要翻译： 由式[1]表示的化合物：其中环A和环B各自表示任选取代的苯环; 环C表示任选进一步取代的芳环; R 1表示任选被任选取代的羟基取代的低级烷基; X 1a表示键或任选取代的低级亚烷基; X 1b表示键或任选取代的低级亚烷基; x 2表示键，-O-或-S-; X 3表示键或任选取代的二价烃基; Y表示任选酯化或酰胺化的羧基，或其盐。 式[I]的化合物更安全并且具有更强的降脂活性，例如角鲨烯合酶抑制活性（降胆固醇活性）和甘油三酯降低活性，因此它是可用作预防或治疗高脂血症的药剂的化合物。

    MEDICAL INFORMATION SYSTEM
    6.
    发明申请
    MEDICAL INFORMATION SYSTEM 审中-公开
    医疗信息系统

    公开(公告)号：US20080058612A1

    公开(公告)日：2008-03-06

    申请号：US11849773

    申请日：2007-09-04

    申请人： Shigeharu Ohyu ,  Yasuo Sakurai ,  Satoshi Ikeda ,  Kousuke Sakaue ,  Hitoshi Yamagata ,  Yoshihisa Nakada ,  Toshio Tanaka

    发明人： Shigeharu Ohyu ,  Yasuo Sakurai ,  Satoshi Ikeda ,  Kousuke Sakaue ,  Hitoshi Yamagata ,  Yoshihisa Nakada ,  Toshio Tanaka

    IPC分类号： A61B5/00 ,  G06Q50/00

    CPC分类号： G06F19/3456 ,  A61B5/0059 ,  A61B5/1107 ,  A61B5/4821 ,  G06Q50/22 ,  G16H50/50

    摘要： A medical information system includes a measurement unit that measures at least the positions of medical instruments and biomedical information, a medical act identification unit that decides the types of performed medical acts and the time instants of performance, at which the medical acts are performed, on the basis of the measured positions of the medical instruments and the measured biomedical information, and a medical stage identification unit that decides the types of medical stages, into which a flow of steps starting with a step of preparing for surgery and ending with a step of completing the surgery is divided in terms of the purpose of work, and the time instants of the medical stages on the basis of the decided types of medical acts, the decided time instants of performance, the other types of medical stages that have already been decided, and the time instants of the other types of medical stages that have already been decided.

    摘要翻译： 医疗信息系统包括至少测量医疗器械和生物医学信息的位置的测量单元，确定执行医疗行为的类型的执行医疗行为的类型和执行医疗行为的时间表的医疗行为识别单元 医疗仪器的测量位置的基础和所测量的生物医学信息，以及医疗阶段识别单元，其决定医疗阶段的类型，从步骤准备步骤开始的步骤流程，并以步骤 完成手术在工作目的和医疗阶段的时间根据决定的医疗行为类型，决定的时间表现，已经决定的其他类型的医疗阶段进行分割 ，以及已经决定的其他类型医疗阶段的时间表。

    Heterocyclic derivative and use thereof
    8.
    发明授权
    Heterocyclic derivative and use thereof 失效
    杂环衍生物及其用途

    公开(公告)号：US08461348B2

    公开(公告)日：2013-06-11

    申请号：US12936291

    申请日：2009-04-03

    申请人： Nobuyuki Matsunaga ,  Yoshihisa Nakada ,  Yusuke Ohba ,  Hideyuki Nakagawa

    发明人： Nobuyuki Matsunaga ,  Yoshihisa Nakada ,  Yusuke Ohba ,  Hideyuki Nakagawa

    IPC分类号： C07D277/20 ,  C07D277/62 ,  A61K31/425

    CPC分类号： C07D263/32 ,  C07D271/04 ,  C07D271/10 ,  C07D277/20 ,  C07D277/30 ,  C07D285/12 ,  C07D307/54 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14

    摘要： The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like.An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.

    摘要翻译： 本发明旨在提供具有优异的药理作用，理化特性等并可用作sGC活化药物或用于预防和/或治疗高血压，缺血性心脏病，心力衰竭，肾脏等疾病的药剂的化合物 疾病，动脉硬化疾病，心房颤动，肺动脉高压，糖尿病，糖尿病并发症，代谢综合征，外周动脉阻塞，勃起功能障碍等。 含有由式（II）表示的化合物的sGC活化药物：其中每个符号如说明书中所定义，或其盐作为活性成分。